Join the club for FREE to access the whole archive and other member benefits.

Ovid Therapeutics

Company focused on developing medicines that transform the lives of people living with rare neurological disorders

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs).

Visit website: https://ovidrx.com/

 ovid-therapeutics

 OvidRx

 UCSt_qcZ5kRFb1KUaTZ-iVPA

Details last updated 11-Jun-2022

People at Ovid Therapeutics

Jeremy M. Levin

Chairman and CEO at Ovid Therapeutics Inc